AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · Real-Time Price · USD
1.120
+0.030 (2.75%)
Feb 27, 2026, 4:00 PM EST - Market closed
AEON Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
28.34M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kyntra Bio | 8.30M |
| Evaxion | 7.65M |
| Marker Therapeutics | 4.69M |
| Dyadic International | 3.34M |
| IGC Pharma | 1.11M |
AEON News
- 5 weeks ago - AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions - GlobeNewsWire
- 2 months ago - AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - GlobeNewsWire
- 2 months ago - AEON Biopharma Announces Execution of Exchange Agreement with Daewoong - GlobeNewsWire
- 3 months ago - AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling - GlobeNewsWire
- 3 months ago - AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth - GlobeNewsWire
- 3 months ago - AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes - GlobeNewsWire
- 5 months ago - AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19 - GlobeNewsWire
- 7 months ago - AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire